2026 NPPES data Hematology & Oncology Physician NPI 1689782708 M.D.
Verify on CMS →

FARIBORZ MORTAZAVI, M.D.

Hematology & Oncology Physician in OXNARD, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
1K
Medicare Part D claims · 170 beneficiaries · Hematology & Oncology Physician avg: 847
MIPS score
100/100
▲ 17 pts above national avg 83.1 · [object Object]
Industry payments
$3.4K
148 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

FARIBORZ MORTAZAVI, M.D. reported a CMS MIPS final score of 100/100 — above the 83.1 national average — and filed 1,083 Medicare Part D claims in 2023.

100/100
MIPS score · +17 vs avg
1K
Part D claims, 2023
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

FARIBORZ MORTAZAVI, M.D.'s MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

100 Top 7% higher than 93% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

FARIBORZ MORTAZAVI, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about FARIBORZ MORTAZAVI, M.D.?

High performer (top quartile)

NPI registry status

Active

Issued 08/28/2006

NPI 1689782708

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

1,083 28% vs specialty avg

2023 prescription claims

Specialty avg: 847

MIPS final score

100/100 16.900000000000006% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in California

How Hematology & Oncology Physician compares to other specialties among California providers

California providers

Hematology & Oncology Physician share within California

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within California

Medicare quality performance — MIPS

FARIBORZ MORTAZAVI, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average

High performer (top quartile)
MIPS Final Score
100/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Hematology & Oncology Physician) — 100/100 vs national avg 83.1

0%100%National avg83%99%
MIPS final score (Hematology & Oncology Physician) — 100/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

FARIBORZ MORTAZAVI, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 1700 N ROSE AVE SUITE 320, OXNARD, CA, 93030, with a listed phone of (805) 485-8709. NPI 1689782708 was issued on 08/28/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what MORTAZAVI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 1,083 prescription claims written by this provider, covering 170 Medicare beneficiaries and totaling roughly $3.5 million in drug spend, with an opioid prescribing rate of 7.8%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 100, Cost 95.778), compared with the national average of 83.1.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1700 N ROSE AVE SUITE 320
OXNARD, CA 93030

Provider Details

NPI 1689782708
Specialty Hematology & Oncology Physician
Credentials M.D.
Gender Male
NPI Issued 08/28/2006

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

100
Final Score
Avg: 83.1
100
Quality
95.778
Cost

Reporting: Individual

Hospital and facility affiliations

Facilities where FARIBORZ MORTAZAVI, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

PMK MEDICAL GROUP, INC.
OXNARD, CA

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for FARIBORZ MORTAZAVI, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$3.4K

Largest payer

PFIZER INC.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to FARIBORZ MORTAZAVI, M.D.. To verify FARIBORZ MORTAZAVI, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

1,083
Total Claims
$3.5M
Total Drug Cost
170
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,500
Total Day Supply
41,192
Generic Drug Cost
$241K
Opioid Claims
85 (7.8% rate)
Antibiotic Claims
28

Patient Demographics

Average Patient Age
75.5 years
Avg HCC Risk Score
2.30
Gender Split
60% female / 40% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What FARIBORZ MORTAZAVI, M.D. prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Anastrozole
88
Prednisone
67
Alendronate Sodium
57
Hydrocodone-Acetaminophen
Hydrocodone/Acetaminophen
57
Levothyroxine Sodium
50
Gabapentin
41
Xarelto
Rivaroxaban
38
Exemestane
34
Hydroxyurea
32
Megestrol Acetate
32

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How FARIBORZ MORTAZAVI, M.D. fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

FARIBORZ MORTAZAVI, M.D.'s 1,083 claims are above the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as MORTAZAVI.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is FARIBORZ MORTAZAVI, M.D.'s specialty?
FARIBORZ MORTAZAVI, M.D. specializes in Hematology & Oncology Physician and practices in OXNARD, California. Credentials: M.D..
How much does FARIBORZ MORTAZAVI, M.D. prescribe under Medicare Part D?
In 2023, FARIBORZ MORTAZAVI, M.D. wrote 1,083 Medicare Part D claims totaling $3.5M in drug costs for 170 beneficiaries.
What is FARIBORZ MORTAZAVI, M.D.'s Medicare quality score?
FARIBORZ MORTAZAVI, M.D. has a CMS MIPS Final Score of 100/100 (Quality: 100, Cost: 95.778). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is FARIBORZ MORTAZAVI, M.D. located?
FARIBORZ MORTAZAVI, M.D. is located at 1700 N ROSE AVE SUITE 320, OXNARD, CA, 93030. Phone: (805) 485-8709.
What is FARIBORZ MORTAZAVI, M.D.'s NPI number?
FARIBORZ MORTAZAVI, M.D.'s National Provider Identifier (NPI) is 1689782708, issued on 08/28/2006.
Does FARIBORZ MORTAZAVI, M.D. prescribe opioids?
Yes, FARIBORZ MORTAZAVI, M.D. had 85 opioid claims in 2023 with an opioid prescribing rate of 7.8%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does FARIBORZ MORTAZAVI, M.D. prescribe most often?
Based on 2023 Medicare Part D data, FARIBORZ MORTAZAVI, M.D.'s most frequently prescribed drugs include Anastrozole, Prednisone, Alendronate Sodium. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does FARIBORZ MORTAZAVI, M.D. accept Medicare?
FARIBORZ MORTAZAVI, M.D. appears in CMS Medicare data with 1,083 Part D claims and 170 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify FARIBORZ MORTAZAVI, M.D.'s credentials?
FARIBORZ MORTAZAVI, M.D.'s NPI is 1689782708 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology